Last reviewed · How we verify

The standard therapy

Kafrelsheikh University · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

The standard therapy is a Small molecule drug developed by Kafrelsheikh University. It is currently FDA-approved.

A standard therapy for conditions such as cerebral palsy, muscle disorder, physical disability, posture disorders in children, and spina bifida involves high intensity circuit training (HICT) and loaded high intensity training. The therapy is a small molecule modality, as indicated by its listing on ChEMBL.

At a glance

Generic nameThe standard therapy
SponsorKafrelsheikh University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about The standard therapy

What is The standard therapy?

The standard therapy is a Small molecule drug developed by Kafrelsheikh University.

Who makes The standard therapy?

The standard therapy is developed and marketed by Kafrelsheikh University (see full Kafrelsheikh University pipeline at /company/kafrelsheikh-university).

What development phase is The standard therapy in?

The standard therapy is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing